Search Tag: wegovy

Cardiology Management

2024 22 May

  A recent analysis shows that semaglutide, a prescription drug (brand names Wegovy and Ozempic), may reduce the risk of heart attacks and strokes in individuals, regardless of their weight loss success.   Prof John Deanfield from the UCL Institute of Cardiovascular Disease led the study. Researchers analysed data from the Semaglutide and...Read more

Cardiology Management

2023 05 Sep

Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss medication Wegovy (active ingredient - semaglutide), has become Europe's most valuable company, dethroning the French luxury conglomerate LVMH.   Following the successful launch of Wegovy in the U.K., the company's shares saw a significant uptick in value. As trading closed...Read more